I just downloaded the article. The preprint I have access to is 94 pages so it is very comprehensive
Its really a Precision Medicine AD article and there is very little about Anavex (or any medication) in long detail. Searching on Anavex gets 3 results. Two are the disclosures for Hampel and Cummings and the third is the Anavex entry in Table 1G Cellular pathway signal modulators. About 100 different drugs are mentioned in the Table 1a to Table 1h.
A mixed ligand for
s1 /muscarinic receptors acting
as agonist and enhancing most
of their cytoprotective
pathways: calcium homeostasis,
mitochondrial function and ER
stress response. In addition, it
modulates the axis
AKT/PI3/GSK-3ß
Downregulation of GSK3 ß
leads to block tau
hyperphosphorylation, thus
enhancing ADAM17 expression
and reducing BACE1
expression with reduced cellular
Aß toxic monomers load
Potential effect of downstream
transcription factors activated
by GSK3 that are involved in
pro-inflammatory response
(STAT, NFkB)[293,294]
The disclosures:
HH serves as Senior Associate Editor for the Journal Alzheimer’s & Dementia; he received
lecture fees from Biogen and Roche, research grants from Pfizer, Avid, and MSD Avenir (paid to
the institution), travel funding from Axovant, Eli Lilly and company, Takeda and Zinfandel, GEHealthcare
and Oryzon Genomics, consultancy fees from Jung Diagnostics, Cytox Ltd., Axovant,
Anavex, Takeda and Zinfandel, GE Healthcare and Oryzon Genomics, and participated in scientific
advisory boards of Axovant, Eli Lilly and company, Cytox Ltd., GE Healthcare, Takeda and
Zinfandel, Oryzon Genomics and Roche Diagnostics.
and
JC has provided consultation to AbbVie, Acadia, Actinogen, Alzheon, Anavex, Avanir,
Axovant, Biogen, Boehinger-Ingelheim, Bracket, Dart, Eisai, Genentech, Kyowa, Lilly, Lundbeck,
Medavante, Merck, Orion, Otsuka, Pfizer, QR, Roche, Suven, and Takeda pharmaceutical and
assessment companies.
Sigma or the greek sigma shows up in two references and the Anavex entry / Table legend
AI
Market Data 
Markets 
